The Cornell cardiovascular data technology spinout has launched with $54m in funding, $43m coming from an American College of Cardiology-backed series B round.
Cleerly, a US-based developer of machine learning algorithms for heart disease detection, received $43m yesterday in a series B round that included American College of Cardiology.
The round was led by venture capital firm Vensana Capital and also featured Cigna Ventures, the corporate venturing arm of healthcare services provider Cigna, as well as LRVHealth, New Leaf Venture Partners and DigiTx Partners, along with unnamed existing investors.
Founded in 2017, Cleerly uses proprietary artificial intelligence and machine learning algorithms to extract and integrate data from computerised tomography (CT) imaging to support clinical diagnosis, prognostication and the prevention of heart attacks.
The company’s core product, Cleerly Coronary, is capable of quantifying and characterising the presence, extent, severity and type of plaque build-up in addition to coronary artery disease and other cardiovascular disorders.
Cleerly’s algorithms are based on research at Weill Cornell Medicine, the medical school at Cornell University,…
